Entropin, Inc.

ENT-103 reported effective in preclinical model for pain

Published in FDA Law Weekly, December 16th, 2004

Entropin, Inc., (ETOP), announced that Dr. Jacqueline Sagen, professor of neurosurgery at University of Miami School of Medicine's Miami Project to Cure Paralysis, and her colleagues presented the results of their preclinical testing of Entropin's drug candidate, ENT-103, in the formalin model for neurogenic inflammatory pain at the Society for Neuroscience conference held October 27, 2004 in San Diego, California.

"We found a significant dose-related antinociceptive activity of ENT-103, which attenuated both phase I (acute pain) and phase II (tonic pain) of the formalin response when administered subcutaneously (under the skin)," said Sagen. "These results indicate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of FDA Law Weekly

Source: FDA Law Weekly (2004-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry